Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Lamba, Gurpreet ^a   Ambrale, Samir ^a   Lee, Byung ^a   Gupta, Ridhi ^a   Rafiyath, Shamudheen M ^a   Liu, Delong ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRENOLANIB; DASATINIB; EVEROLIMUS; GANETESPIB; IMATINIB; MASITINIB; MOTESANIB; NILOTINIB; PERIFOSINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RAPAMYCIN; REGORAFENIB; RETASPIMYCIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; VATALANIB;

ABDOMINAL PAIN; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BRAIN HEMORRHAGE; CANCER REGRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LIVER FUNCTION TEST; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; RASH; REVIEW; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84860631629     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-21     Document Type: Review

References (65)

1. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Rubin BP, Fletcher JA, Fletcher CD, Int J Surg Pathol 2000 8 1 5 10 10.1177/106689690000800105 11493959 (Pubitemid 30129563)
2. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, OLeary TJ, Remotti H, Rubin BP, et al. Hum Pathol 2002 33 5 459 465 10.1053/hupa.2002.123545 12094370 (Pubitemid 34747864)
3. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Miettinen M, El-Rifai W, L HLS, Lasota J, Hum Pathol 2002 33 5 478 483 10.1053/hupa.2002.124123 12094372 (Pubitemid 34747866)
4. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. Science 1998 279 5350 577 580 10.1126/science.279.5350.577 9438854 (Pubitemid 28067289)
5. PDGFRA activating mutations in gastrointestinal stromal tumors. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. Science 2003 299 5607 708 710 10.1126/science. 1079666 12522257 (Pubitemid 36159485)
6. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y, Gastroenterology 2003 125 3 660 667 10.1016/S0016-5085(03)01046-1 12949711 (Pubitemid 37070684)
7. BRAF mutation status in gastrointestinal stromal tumors. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY, Coindre JM, Am J Clin Pathol 2010 133 1 141 148 10.1309/AJCPPCKGA2QGBJ1R 20023270
8. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP, J Clin Pathol 2009 62 7 613 616 10.1136/jcp.2009.064550 19561230
9. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, et al. Proc Natl Acad Sci U S A 2011 108 1 314 318 10.1073/pnas.1009199108 21173220
10. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, et al. J Natl Compr Canc Netw 2010 8 Suppl 2 1 41 quiz S42-44 20947719
11. National Comprehensive Cancer Network Guidelines. NCCN, National Comprehensive Cancer Network Guidelines 2012 2012 2 2012
12. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. N Engl J Med 2002 347 7 472 480 10.1056/NEJMoa020461 12181401 (Pubitemid 34879334)
13. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato-di-Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, et al. Lancet 2001 358 9291 1421 1423 10.1016/S0140-6736(01)06535-7 11705489 (Pubitemid 33055745)
14. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al. J Clin Oncol 2008 26 4 626 632 10.1200/JCO.2007.13.4452 18235122 (Pubitemid 351264358)
15. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, et al. Lancet 2004 364 9440 1127 1134 10.1016/S0140-6736(04)17098-0 15451219 (Pubitemid 39296599)
16. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, et al. J Clin Oncol 2005 23 24 5795 5804 10.1200/JCO.2005.11.601 16110036
17. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Wozniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, et al. J Cancer Res Clin Oncol 2007 133 9 589 597 10.1007/s00432-007-0202-4 17458563 (Pubitemid 47077050)
18. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease?-single center experience. Armbrust T, Sobotta M, Gunawan B, Fuzesi L, Langer C, Cameron S, Ramadori G, Eur J Gastroenterol Hepatol 2009 21 7 819 823 10.1097/MEG.0b013e32830b0f76 19369884
19. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al. J Clin Oncol 2003 21 23 4342 4349 10.1200/JCO.2003.04.190 14645423 (Pubitemid 46621810)
20. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, et al. Eur J Cancer 2004 40 5 689 695 10.1016/j.ejca.2003.11.025 15010069 (Pubitemid 38326618)
21. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC, J Clin Oncol 2005 23 23 5357 5364 10.1200/JCO.2005.14.068 15928335 (Pubitemid 46206989)
22. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, et al. J Clin Oncol 2008 26 33 5360 5367 10.1200/JCO.2008.17.4284 18955451
23. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, et al. Eur J Cancer 2006 42 8 1093 1103 10.1016/j.ejca.2006.01.030 16624552 (Pubitemid 44275331)
24. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Gastrointestinal Stromal Tumor Meta-Analysis G, J Clin Oncol 2010 28 7 1247 1253 20124181
25. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, Group EGW, Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2009 20 Suppl 4 64 67
26. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, et al. J Clin Oncol 2007 25 9 1107 1113 10.1200/JCO.2006.09. 0183 17369574 (Pubitemid 46596763)
27. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, et al. Lancet Oncol 2010 11 10 942 949 10.1016/S1470-2045(10)70222-9 20864406
28. Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. Le Cesne A, Ray-Coquard IL, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Cupissol D, Chevreau C, Bompas E, et al. ASCO Meeting Abstracts 2011 29 15 -uppl 10015
29. Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial. Domont J, Blay J, Ray-Coquard IL, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Cupissol D, Chevreau C, et al. ASCO Meeting Abstracts 2011 29 15-suppl 10054
30. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, et al. J Clin Oncol 2006 24 29 4764 4774 10.1200/JCO.2006.06.2265 16954519 (Pubitemid 46630941)
31. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, et al. Clin Cancer Res 2007 13 18 Pt 1 5398 5405 17875769 (Pubitemid 47510366)
32. Drug transporters and imatinib treatment: implications for clinical practice. Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH, Clin Cancer Res 2011 17 3 406 415 10.1158/1078-0432.CCR-10-2250 21163869
33. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM, J Clin Oncol 2006 24 15 2325 2331 10.1200/JCO.2005.05.3439 16710031 (Pubitemid 46630664)
34. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD, Radiology 2005 235 3 892 898 10.1148/radiol.2353040332 15833985 (Pubitemid 40695886)
35. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR, et al. Eur J Cancer 2005 41 12 1751 1757 10.1016/j.ejca.2005.04.034 16098458 (Pubitemid 41132637)
36. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, et al. Gastroenterology 2005 128 2 270 279 10.1053/j.gastro.2004.11.020 15685537 (Pubitemid 40431080)
37. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, et al. Clin Cancer Res 2009 15 18 5902 5909 10.1158/1078-0432.CCR-09-0482 19737946
38. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Lancet 2006 368 9544 1329 1338 10.1016/S0140-6736(06)69446-4 17046465 (Pubitemid 44528723)
39. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. Kindler HL, Campbell NP, Wroblewski K, Maki RG, DAdamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE, ASCO Meeting Abstracts 2011 29 15-suppl 10009
40. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, et al. Ann Oncol 2012 23
41. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, Park SR, Kang BY, Kang YK, Invest New Drugs 2012 30 21499733
42. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Trent JC, Wathen K, von Mehren M, Samuels BL, Staddon AP, Choy E, Butrynski JE, Chugh R, Chow WA, Rushing DA, et al. ASCO Meeting Abstracts 2011 29 15-suppl 10006
43. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, et al. Clin Cancer Res 2009 15 22 6862 6870 10.1158/1078-0432.CCR-09-1315 19861442
44. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, et al. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2008 19 1 173 177
45. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Montemurro M, Schoffski P, Reichardt P, Gelderblom H, Schutte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, et al. Eur J Cancer 2009 45 13 2293 2297 10.1016/j.ejca.2009.04.030 19467857
46. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schoffski P, Marynen P, Debiec-Rychter M, Clin Cancer Res 2008 14 18 5749 5758 10.1158/1078-0432.CCR-08-0533 18794084
47. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, et al. Clin Cancer Res 2009 15 18 5910 5916 10.1158/1078-0432.CCR-09-0542 19723647
48. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Benjamin RS, Schoffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, et al. Cancer Chemother Pharmacol 2011 68 1 69 77 10.1007/s00280-010-1431-9 20838998
49. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. Wiebe L, Kasza KE, Maki RG, DAdamo DR, Chow WA, Wade JL, Agamah E, Stadler WM, Vokes EE, Kindler HL, ASCO Meeting Abstracts 2008 26 15-suppl 10502
50. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). Campbell NP, Wroblewski K, Maki RG, DAdamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE, Kindler HL, ASCO Meeting Abstracts 2011 29 4-suppl 4
51. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Guo T, Agaram NP, Wong GC, Hom G, DAdamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, et al. Clin Cancer Res 2007 13 16 4874 4881 10.1158/1078-0432.CCR-07-0484 17699867 (Pubitemid 47294795)
52. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, et al. ASCO Meeting Abstracts 2011 29 15-suppl 10007
53. Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. Blay J, Le Cesne A, Bin-Bui N, Bouche O, Adenis A, Julien D, Cioffi A, Moussy A, Hermine O, ASCO Meeting Abstracts 2011 29 4-suppl 85
54. The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. Heinrich MC, Griffith D, McKinley A, Presnell A, Ramachandran A, ASCO Meeting Abstracts 2011 29 15-suppl 10012
55. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, et al. Eur J Cancer 2010 46 8 1344 1351 10.1016/j.ejca.2010.02.014 20211560
56. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB, J Clin Oncol 2009 27 31 5262 5269 10.1200/JCO.2009.21.8487 19738123
57. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Schoffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A, Demetri GD, Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2010 21 10 1990 1998 10.1093/annonc/mdq076
58. A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update. van Oosterom A, Reichardt P, Blay J-Y, Dumez H, Fletcher J, Debiec-Rychter M, Shand N, Drimitrijevic S, Yap A, Demetri G, ASCO Meeting Abstracts 2005 23 16-suppl 9033
59. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. Richter S, Pink D, Hohenberger P, Schuette H, Casali PG, Pustowka A, Reichardt P, ASCO Meeting Abstracts 2010 28 15-suppl 10038
60. Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). Piovesan C, Fumagalli E, Coco P, Palassini E, Dileo P, Morosi C, Gronchi A, Casali P, ASCO Meeting Abstracts 2009 27 15S 10565
61. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. Demetri GD, Heinrich MC, Chmielowski B, Morgan JA, George S, Bradley R, Blackman RK, Teofilovici F, Fletcher JA, Tap WD, et al. ASCO Meeting Abstracts 2011 29 15-suppl 10011
62. Final results from a Phase III study of IPI504 retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of tyrosine kinase inhibitor (TKI) therapies. Demetri G, Le Cesne A, von Mehren M, et al. ASCO Gastrointestinal Cancers Symposium Meeting abstracts 2010 28 15-suppl 64
63. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Conley AP, Araujo D, Ludwig J, Ravi V, Samuels BL, Choi H, Thall PF, Patel S, Benjamin R, Trent J, ASCO Meeting Abstracts 2009 27 15S 10563
64. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Bauer S, Yu LK, Demetri GD, Fletcher JA, Cancer Res 2006 66 18 9153 9161 10.1158/0008-5472.CAN-06-0165 16982758 (Pubitemid 44521135)
65. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. Demetri GD, George S, Morgan JA, Wagner A, Quigley MT, Polson K, Pokela J, van den Abbeele A, Adams J, Grayzel D, ASCO Meeting Abstracts 2007 25 18-suppl 10024